Real-world clinical characterization of subjects with depression treated with antidepressant drugs focused on (non-)genetic factors, pharmacokinetics, and clinical outcomes: GnG-PK/PD-AD study.
Sign Up to like & getrecommendations! Published in 2019 at "Experimental and clinical psychopharmacology"
DOI: 10.1037/pha0000294
Abstract: This work aimed to describe and characterize the GnG-PK/PD-AD study and the population of subjects diagnosed with depression and treated with fluoxetine, paroxetine, and venlafaxine recruited in the scope of this project, particularly in terms… read more here.
Keywords: depression; pharmacokinetics clinical; gng study; clinical outcomes ... See more keywords
Exenatide: pharmacokinetics, clinical use, and future directions
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1282463
Abstract: ABSTRACT Introduction: The first-in-class glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide, which was initially approved in 2005, is available in twice-daily (BID) and once-weekly (QW) formulations. Clinical trial data suggest both formulations are effective and safe… read more here.
Keywords: pharmacokinetics clinical; clinical use; glp 1ras; exenatide pharmacokinetics ... See more keywords
Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Current pharmaceutical design"
DOI: 10.2174/1381612824666181018153641
Abstract: BACKGROUND New Oral Anticoagulants (NOACs) are effective and widely used to prevent and treat thromboembolic diseases, but the response to NOACs differs according to ABCB1 genotypes. OBJECTIVE We investigated the effects of ABCB1 genotypes on… read more here.
Keywords: pharmacokinetics clinical; clinical outcomes; review; abcb1 genotypes ... See more keywords